Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Journal of Clinical Medicine|November 13, 2025
Sex-Specific Real-Life Profiling in Vedolizumab, Ustekinumab, and Tofacitinib Effectiveness in Ulcerative ColitisAntonio Tursi, Raffaele Pellegrino, Giammarco Mocci, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 7, 2014
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one yearLuisa Guidi, Manuela Marzo, Gianluca Andrisani, et al.
Minerva Gastroenterologica E Dietologica|March 16, 2017
Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centersAntonio Tursi, Leonardo Allegretta, Stefania Chiri, et al.
Journal of Crohn'S & Colitis|April 3, 2012
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agentsAlfredo Papa, Carla Felice, Manuela Marzo, et al.
Digestive Diseases (Basel, Switzerland)|April 24, 2008
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspectsAlfredo Papa, Franco Scaldaferri, Silvio Danese, et al.
Therapeutic Advances in Gastroenterology|June 18, 2026
An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patientsAntonio Tursi, Andrea Pasta, Walter Elisei, et al.
Journal of Clinical Medicine|March 11, 2023
Insights into Mesalazine Use in Clinical Practice of Young GastroenterologistsOlga Maria Nardone, Giovanni Marasco, Loris Riccardo Lopetuso, et al.
Biomed Research International|September 25, 2013
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agentsLuisa Guidi, Carla Felice, Annabella Procoli, et al.
European Journal of Gastroenterology & Hepatology|June 26, 2025
Adherence to clinical and endoscopic standards of quality in inflammatory bowel disease: a nationwide survey from the Italian Association of Hospital Gastroenterologists and EndoscopistsMaria Carla Di Paolo, Andrea Cassinotti, Cristiano Pagnini, et al.
Biomedicines|July 27, 2022
Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational StudyGiammarco Mocci, Giorgia Bodini, Leonardo Allegretta, et al.
Pageof 7